Results 181 to 190 of about 133,012 (307)

Comparative Clinical Trajectories Across Cannabis‐Related and Nonsubstance‐Related Psychoses

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Research indicates that first‐episode psychosis (FEP) with cannabis use disorder (CUD) carries a substantial disease burden, but more granular clinical trajectories of cannabis‐related psychoses remain unclear. This study examines the clinical trajectories of first clinically diagnosed FEP&CUD and cannabis‐induced psychosis (CIP) in
Antti Mustonen, Solja Niemelä, Alexander Denissoff, Antti Tanskanen, Ellenor Mittendorfer‐Rutz, Markku Lähteenvuo, Jari Tiihonen, Heidi Taipale   +7 more
wiley   +1 more source

Antipsychotic prescribing trends in England: role of regional disparities, health inequalities and ethnic density. [PDF]

BJPsych Open
Khan MU, Hasan SS, Maidment I, Husain N.
europepmc   +1 more source

Selective Serotonin Reuptake Inhibitor Treatment in Adolescence and Subsequent Risk of Nonaffective Psychosis: A Quasi‐Experimental Study

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Objective Psychotic disorders are frequently preceded by common mental disorders (CMDs), like depression and anxiety. It remains unclear whether treating CMDs in adolescence can reduce subsequent psychosis risk. We applied quasi‐experimental methods to national register data to assess whether a causal relationship exists between selective ...
Ioanna Kougianou, Animesh Talukder, Kirstie O′ Hare, Colm Healy, Ian Kelleher   +4 more
wiley   +1 more source

A systematic review using the Theoretical Domains Framework to identify barriers and facilitators to the adoption of prescribing guidelines

International Journal of Pharmacy Practice, EarlyView., 2020
Abstract Objectives Evidence‐based guidelines have the potential to reduce variation and increase prescribing quality. Identifying the key determinants to their uptake, using a theory‐based approach, may assist in the design of successful interventions to increase their adoption into practice.
Paulina Paksaite, Margaret Watson, Joel Crosskey, Eni Sula, Celine West   +4 more
wiley   +1 more source

Catatonia treatments and risk of recurrence. [PDF]

J Affect Disord
Patarroyo-Rodriguez L, Duque L, Pazdernick VK, Burson JR, Singh B.   +4 more
europepmc   +1 more source

Psychiatric History and Postpartum Depression: The Mediating Role of Obstetric Complications

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Psychiatric history is the strongest risk factor for postpartum depression (PPD). Obstetric complications, more prevalent among women with a psychiatric history, are also independent risk factors. However, the mechanisms linking these factors to PPD remain unclear.
Mette‐Marie Zacher Kjeldsen, Katrine Holde, Line Bager, Veerle Bergink, Emely Ek Blæhr, Janne Tidselbak Larsen, Kathrine Bang Madsen, Merete Lund Mægbæk, Liselotte Vogdrup Petersen, Trine Munk‐Olsen   +9 more
wiley   +1 more source

Effect of psychotropic medications on suicide-related outcomes: a systematic review and meta-analysis of observational studies. [PDF]

EClinicalMedicine
Kozhevnikova S, Emilian C, Scola G, Chang Z, Yukhnenko D, Fazel S.   +5 more
europepmc   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Pharmacological Incongruity of Lacosamide in the Management of Delirium Complicated by Ileus. [PDF]

Neuropsychopharmacol Rep
Nagamine T.
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source